BioSpace News Archive

Standigm Inc., a leading Korean Artificial Intelligence company for drug discovery, announces that it has closed $44.5 million in a pre-IPO funding round co-led by SKS PE and Daishin Private Equity.

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Timber’s Chief Executive Officer John Koconis will present a corporate overview at the virtual 2021 H.C. Wainwright Global Life Sciences Conference

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced that enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS.

Children born to women taking certain medications for epilepsy during pregnancy have no developmental delays at age three when compared to children of healthy women without epilepsy, according to a preliminary study released March 4, 2021, that will be presented at the American Academy of Neurology’s 73rd Annual Meeting being held virtually April 17 to 22, 2021.

Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on advancing spine surgery and improving patient outcomes, including through the application of digital technology, today announced that it is changing its earnings release and conference call date for the fourth quarter and full year 2020

Health Canada received an application from Janssen Inc. for authorization of its COVID-19 vaccine on November 30, 2020.

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now participating in the Company’s international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the completion of enrollment of patients in Part 1 of its registrational Proof of Concept study of SLS-002

Economic activity in the hospital subsector grew in February for the ninth consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

Elekta announced that its latest solution for proton therapy, Monaco®* treatment planning for protons, has received 510 clearance from the U.S. Food and Drug Administration.